Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity

Arthritis and Rheumatism

Volumn 39, Issue 7, 1996, Pages 1178-1188

  Manzi, Susan ^a,d   Rairie, Joan E ^a   Carpenter, A Betts ^a   Kelly, Robert H ^a   Jagarlapudi, Santhi P ^a   Sereika, Susan M ^b   Medsger Jr , Thomas A ^a   Ramsey Goldman, Rosalind ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Liliane Kaufmann Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3D; COMPLEMENT C4; COMPLEMENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0030000994     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390716     Document Type: Article

References (37)

1. Buyon JP, Tamerius J, Belmont HM, Abramson SB: Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Arthritis Rheum 35:1028-1037, 1992
2. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A: Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312: 1594-1599, 1985
3. Senaldi G, Makindc VA, Vergani D, Isenberg DA: Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 47:913-917, 1988
4. Gawryl MS, Chudwin DS, Langlois PF, Lint TF: The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 31:188-195, 1988
5. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S: Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate exacerbations of disease. Arthritis Rheum 29:1085-1089, 1986
6. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB: Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31:632-641, 1988
7. Porcel JM, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo MJ, Gene T, Warhurton F, Kraus M, Vergani D: The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 74:283-288, 1995
8. Kerr LD, Adelsberg BR, Spiera H: Complement activation in systemic lupus erythematosus: a marker of inflammation. J Rheumatol 13:313-319, 1986
9. Rother E, Lang B, Coldewey R, Hartung K, Peter HH: Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 12:31-35, 1993
10. Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, Daha MR, van Es LA: The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 28:904-913, 1985
11. Schur PH: Complement and lupus erythematosus. Arthritis Rheum 25:793-798, 1982
12. Penin LH, Lambert PH, Miescher PA: Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 56:165-176, 1975
13. Nusinow SR, Zuraw BL, Curd JG: Hereditary and acquired deficiencies of complement. Med Clin North Am 69:487-504, 1985
14. Fielder AHL, Walport MJ, Batchelor JR, Rynes RI, Black CM, Dodi IA, Hughes GRV: Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. BMJ 286:425-428, 1983
15. Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118, 1989
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992
17. Liang MH, Socher SA, Roberts WN, Esdaile JM: Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31:817-825, 1988
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
19. Pirani CL, Pollak VE: Systemic lupus erythematosus (SLE) glomerulonephritis (lupus nephritis). In, Immunologically Mediated Renal Disease. Edited by RT McCluskey, GA Andres. New York, Marcel Dekker, 1978
20. Tack BF, Janatova J, Thomas ML, Harrison RA, Hammer CH: The third, fourth and fifth components of human complement: isolation and biochemical properties. Methods Enzymol 80:90-91, 1981
21. Schreiver H, Gambino SR: Protein turbidity produced by trichloroacetic acid and sulfosalicylic acid at varying temperatures and varying ratios of albumin and globulin. Am J Clin Pathol 44:667-672, 1965
22. Kelly RH, Vertosick FT: Electrophoretic analysis of proteins. In, Manual of Clinical Laboratory Immunology. Fourth edition. Edited by NR Rose, H Friedman, JL Fahey. Washington, DC, American Society of Microbiology, 1992
23. Kelly RH, Carpenter AB, Sudol KS, Jagarlapudi SP, Manzi S: Complement C3 fragments in urine: detection in systemic lupus erythematosus patients by Western blotting. Appl Theor Electrophor 3:265-269, 1993
24. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8:283-298, 1978
25. Craemer HC: Assessment of 2×2 associations: generalization of signal-detection methodology. Am Statistician 42:37-49, 1988
26. Stachura I, Ellis D, Kelly RH: Urinary immune complexes in patients with glomerular diseases. Arch Pathol Lab Med 107:315-318, 1983
27. Abramson SB, Weissmann G: Complement split products and pathogenesis of SLE. Hosp Pract 15:45-56, 1988
28. Abramson SB, Belmont HM, Hopkins P, Buyon J, Winchester R, Weissmann G: Complement activation and vascular injury in systemic lupus erythematosus. J Rheumatol 14:43-46, 1987
29. Seifter S, Eckert EE: Complement and isohemagglutinins in urinary proteins. J Clin Invest 25:809-813, 1946
30. Peakman M, Lobo-Yeo A, Senaldi G, Nilsson M, Tee DEH, Vergani D: Quantification of C3d in biological fluids by an enzyme-linked immunosorbent assay. J Immunol Methods 104:51-56, 1987
31. Lange K, Wenk EJ: Complement components in the sera and urines of patients with severe proteinuria. Am J Med Sci 228:448-453, 1954
32. Sanders ME, Alexander EL, Koski CL, Frank MM, Joiner KA: Detection of activated terminal complement (C5b-9) in cerebro-spinal fluid from patients with central nervous system involvement of primary Sjögren's syndrome or systemic lupus erythematosus. J Immunol 138:2095-2099, 1987
33. Lund ED, Sorensen LS, Brandslund I: Specificities of monoclonal antibodies against the complement C3d split product. Complement Inflamm 7:18-29, 1990
34. Hemmingsen L, Skaarup P: The 24-hour excretion of plasma proteins in urine of apparently healthy subjects. Scand J Clin Lab Invest 35:347-353, 1975
35. Muso E, Sekita K, Doi T, Kuwahara T, Yoshida H, Tamura T, Kawai C, Hamashima Y: Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis. Clin Immunol Immunopathol 32:351-358, 1984
36. Gado K, Robinson M, Bacon PC, Emery P: C3d estimation in patients with vasculitis: evidence for in vivo complement activation and correlation with disease activity (abstract). Br J Rheumatol 30 (suppl 1):18, 1991
37. Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB: Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 35:55-61, 1992